CFO Moves: Valeant Pharmaceuticals, Zoetis

Valeant Pharmaceuticals International Inc., named Paul Herendeen as its new chief financial officer, luring the executive away from animal-health giant Zoetis Inc., as CFO Journal’s Vipal Monga reported exclusively yesterday. Mr. Herendeen would replace Robert Rosiello, who will remain with the Canadian pharmaceutical company as head of corporate development and strategy. The move is a continuation of the shake-up at the embattled drugmaker. The company didn’t immediately disclose compensation details.

Zoetis, which Mr. Herendeen came out of retirement to join two years ago, named Glenn David, its senior vice president of finance operations, as its new CFO. Mr. David helped take the company public in 2013, and served as acting CFO from April 2014 through August of that year. The company didn’t immediately disclose compensation details.

Content from our sponsorDeloitteCFO insight and analysis written and compiled by Deloitte

Responding to a crisis requires leaders to understand and address numerous concerns in real time, including defining the crisis, determining the cause, and generating options to stop and address impacts. Two critical areas to consider include developing a common operating picture, which provides a single, identical display of relevant information to share across the response team, and prioritizing stakeholders, which can help C-suite leaders develop an engagement strategy.

Please note: The Wall Street Journal News Department was not involved in the creation of the content above.More from Deloitte →